See your results below for :
Brixadi 1ML of 128MG/0.36ML
:
Syringe - 1
Brixadi Coupons & Prices
What is Brixadi ?
Brixadi (buprenorphine) is a once-weekly or once-monthly extended-release injectable medication approved for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product. It functions primarily as a partial agonist at opioid receptors, helping to prevent withdrawal symptoms and reduce opioid cravings. Brixadi is intended to be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.
Brixadi
bue-pre-NOR-feen
Consumer Forms
Injectable
Consumer Routes
By injection
Therapeutic Classes
Anesthetic Adjunct
,
Analgesic
,
Opioid Dependency
- Drowsiness
- Mild nausea, vomiting, constipation, or diarrhea
- Mild nausea
- Pain, itching, burning, swelling, or lump under your skin where the needle is placed
- Pain, itching, burning, swelling, or lump under your skin where the needle is placed or shot given
- Changes in skin color, dark freckles, cold feeling, tiredness, weight loss
- Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing
- Anxiety, restlessness, fever, muscle spasms, twitching, nausea, vomiting, diarrhea, seeing or hearing things that are not there
- Dark urine or pale stools, loss of appetite, yellow skin or eyes
- Blue lips, fingernails, or skin
- Extreme dizziness or weakness, shallow breathing, slow or uneven heartbeat, sweating, cold or clammy skin, seizures
- Fast, slow, or pounding heartbeat
- Severe constipation, stomach pain
- Lightheadedness, dizziness, fainting
- Shaking, trembling, hunger, confusion
- Worsening of pain, increased sensitivity to pain
- Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death
- Serious, life-threatening, or fatal respiratory depression may occur
- Accidental ingestion can result in a fatal overdose of buprenorphine
- Neonatal opioid withdrawal syndrome may occur in newborn infants of mothers who are treated with buprenorphine during pregnancy
- Concomitant use with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death